Iterion Therapeutics

OverviewSuggest Edit

Iterion Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapeutics. It provides Tegavivint, a selective inhibitor of the Wnt/β-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint focuses on desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types.
TypePrivate
Founded2014
HQHouston, TX, US
Websiteiteriontherapeutics.com

Latest Updates

Employees (est.) (Feb 2021)7(+17%)
Cybersecurity ratingBMore

Key People/Management at Iterion Therapeutics

Rahul Aras

Rahul Aras

President and Chief Executive Officer & Director
Casey Cunningham

Casey Cunningham

Chief Medical Officer, Director
Stephen Horrigan

Stephen Horrigan

Chief Scientific Officer
Rose Hernandez

Rose Hernandez

Director of Clinical Operations
Ruolan Han

Ruolan Han

Director, Translational Research
Gowri Sukumar

Gowri Sukumar

Director CMC & Regulatory Affairs
Show more

Iterion Therapeutics Office Locations

Iterion Therapeutics has an office in Houston
Houston, TX, US (HQ)
2450 Holcombe Blvd
Show all (1)

Iterion Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2014

Iterion Therapeutics total Funding

$4.4 m

Iterion Therapeutics latest funding size

$2.60 m

Time since last funding

3 years ago

Iterion Therapeutics investors

Iterion Therapeutics's latest funding round in June 2018 was reported to be $2.6 m. In total, Iterion Therapeutics has raised $4.4 m
Show all financial metrics

Iterion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Iterion Therapeutics Online and Social Media Presence

Embed Graph

Iterion Therapeutics News and Updates

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China

Agreement will expand clinical development for a potent and selective small molecule targeting TBL1, a downstream target in the Wnt/β-catenin signaling pathway Agreement will expand clinical development for a potent and selective small molecule targeting TBL1, a downstream target in the Wnt/β-cateni…

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors

HOUSTON, July 28, 2020 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that enrollment has commenced in its multicenter Phase 2a dose expansion clinical study of Tegavivint, a novel,...

Iterion Therapeutics Blogs

Apollomics, Inc. and Iterion Therapeutics Inc. Announce Exclusive Collaboration and License Agreement in Greater China

Apollomics, Inc. and Iterion Therapeutics Inc. Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivnt in Greater China.

Iterion Therapeutics Frequently Asked Questions

  • When was Iterion Therapeutics founded?

    Iterion Therapeutics was founded in 2014.

  • Who are Iterion Therapeutics key executives?

    Iterion Therapeutics's key executives are Rahul Aras, Casey Cunningham and Stephen Horrigan.

  • How many employees does Iterion Therapeutics have?

    Iterion Therapeutics has 7 employees.

  • Who are Iterion Therapeutics competitors?

    Competitors of Iterion Therapeutics include ImmuNext, Achieve Life Sciences and Anavex.

  • Where is Iterion Therapeutics headquarters?

    Iterion Therapeutics headquarters is located at 2450 Holcombe Blvd, Houston.

  • Where are Iterion Therapeutics offices?

    Iterion Therapeutics has an office in Houston.

  • How many offices does Iterion Therapeutics have?

    Iterion Therapeutics has 1 office.